Walter M. Stadler to Mitogen-Activated Protein Kinase Kinases
This is a "connection" page, showing publications Walter M. Stadler has written about Mitogen-Activated Protein Kinase Kinases.
Connection Strength
0.265
-
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.
Score: 0.108
-
Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia. J Pathol. 2007 Aug; 212(4):386-94.
Score: 0.070
-
Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res. 2001 Apr 01; 61(7):2833-7.
Score: 0.045
-
Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res. 1999 Nov 01; 59(21):5483-7.
Score: 0.041